Cell and Gene Therapy (CGT) Access Model
Active
- Assistance listing
- 93.885
- Agency
-
Centers for Medicare and Medicaid Services
Department of Health and Human Services
- Grant awards
- 8 $28,460,932 in federal obligations
Program facts
- Also known as
- CGT Access Model
- Assistance type
-
- Cooperative Agreement
- Treasury account
-
- 75-0522-0-1-551
- More information
Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.
About this program
The Department of Health and Human Services Centers for Medicare and Medicaid Services (CMS) is awarding Cooperative Agreement funding to support state Medicaid agencies' participation in the Cell and Gene Therapy (CGT) Access Model, with the most recent grant awards made August 1, 2025 (Assistance Listing 93.885).
The program funds state-level implementation of outcomes-based payment agreements between Medicaid programs and manufacturers of cell and gene therapies approved for sickle cell disease treatment. Funded activities include building state agency capacity to administer the model, removing patient-level barriers to care (travel support, childcare assistance, transportation, housing, nutrition), care coordination and patient navigation services, provider and community education campaigns, health outcomes research evaluating equitable access and wraparound service effectiveness, and infrastructure updates to state Medicaid systems including rebate processing, policy development, and contracting with treatment centers.
CMS is the sole funder across the program. Eight Cooperative Agreements totaling $28.5 million in federal dollars obligated have been awarded; all eight grants closed in 2025, resulting in an award cadence of eight grants in 2025. Awards are structured to disburse at recipient discretion over the 10-year-5-month performance period through December 31, 2035. Individual award sizes range from $233 thousand (Vermont) to $9.55 million (Illinois and Connecticut). Recent recipients include the District of Columbia ($4.78 million), Pennsylvania ($6.35 million), Connecticut ($4.93 million), North Carolina ($4.73 million), Illinois ($5.03 million), Mississippi ($979 thousand), Rhode Island ($1.42 million), and Vermont ($233 thousand).
A Notice of Funding Opportunity (CMS-2P2-25-001) was posted June 12, 2024 with an application due date of March 14, 2025. Eligible applicants are states, the District of Columbia, and U.S. territories participating in the Medicaid Drug Rebate Program. Up to $9.55 million per recipient is available, depending on the number of applicants and fund availability. The cooperative agreement structure allows recipients to draw funds at any frequency dependent on internal processes. Applications undergo a 90–120 day review period.
Objective and description
- Objective
The Cell and Gene Therapy (CGT) Access Model aims to improve the lives of people with Medicaid living with rare and severe diseases by increasing access to potentially transformative treatments. It is a multi-year, voluntary model for states and manu
- Description
• Cell and gene therapies can transform the lives of people living with rare and severe diseases that are hard to treat, but gaining access to these potentially life-changing treatments is difficult because they can cost millions of dollars. • The CGT Access Model supports outcomes-based agreements between states and manufacturers that will provide treatments within a framework that lowers prices for states and ties payment to outcomes. • By increasing access to transformative therapies, this model aims to improve the poor health outcomes and low life expectancy associated with rare and severe diseases like sickle cell disease, as well as make it easier for states to pay for cell and gene therapies. • The model underscores CMS' commitment to accelerating access to innovative therapies, improving patient health, and tying payment to outcomes. • Through a Cooperative Agreement award, Implementation Funding will be available to states to support required and optional model implementation activities. Additionally, Milestone Funding will be available to States that successfully complete research projects related to increasing equitable access to sickle cell disease (SCD) gene therapy and promoting multi-disciplinary, comprehensive care for beneficiaries with SCD who are considering or receiving SCD gene therapy. Up to $9.55 million in Cooperative Agreement award funding is anticipated to be available to each selected award recipient over the course of up to 10 years and 5 months (August 1, 2025 - December 31, 2035).
Eligibility
- Applicant eligibility
Eligible applicants are States, the District of Columbia, and any U.S. Territory participating in the Medicaid Drug Rebate Program (MDRP). Eligible applicants must: • Apply to the State Request for Applications (RFA) by no later than March 14, 2025 • Apply to the Notice of Funding Opportunity (NOFO) by no later than March 14, 2025 • Sign a State Agreement with CMS by no later than June 1, 2025
- Beneficiary eligibility
To be eligible for gene therapy to treat sickle cell disease as part of this model, a person must: • Have a documented medical diagnosis for sickle cell disease. • Be enrolled in Medicaid or CHIP (if applicable) in a state participating in the model at time of therapy. • Have Medicaid as their primary payer. • Receive a gene therapy from a participating manufacturer. • Meet standardized prior authorization criteria established through the OBAs.
- Uses of assistance
Cooperative Agreement funding includes two distinct types of financial support: Implementation Funding and Milestone Funding. Implementation Funding is designed to support required and optional model activities that involve staff/contractor time and infrastructure costs, including partnerships with community-based organizations. Milestone Funding is designed to support states that successfully complete research projects related to increasing equitable access to SCD gene therapy and promoting multi-disciplinary, comprehensive care for beneficiaries with SCD who are considering or receiving SCD gene therapy.
- Use restrictions
CMS prohibits the use of Cooperative Agreement funding to reimburse pre-award costs or to supplant existing state, local, tribal, or private funding of state costs. For a full list of all the applicable limitations on the use of funds, please review Sections D6 and F2 of the NOFO. These sections provide comprehensive guidelines to ensure the funds are used appropriately and in alignment with the overall objectives of the CGT Access Model.
- Length and time phasing of assistance
The Cooperative Agreement period of performance is anticipated to be 10.5 years (July 1, 2025 - December 31, 2035). Method of awarding/releasing assistance: Recipients drawdown funds, as necessary, from the Payment Management System (PMS). PMS is the centralized web-based payment system for HHS awards.
How to apply
- Criteria for selecting proposals
For information on application review criteria, please review Section E of the NOFO.
- Award procedure
Awards will be made through Cooperative Agreements. Recipients can draw down at any frequency dependent on their needs/internal processes.
- Deadlines
Applications are due by February 28, 2025, 11:59 pm EST.
- Time to approval or disapproval
Application review period will take 90-120 days.
Grant opportunities
| Opportunity | Status | Posted | Applications due |
|---|---|---|---|
| Cell and Gene Therapy (CGT) Access Model | Closed |
Grant awards
Top recipients by federal obligations
| Rank | Recipient | Federal obligations | Share |
|---|---|---|---|
| 1 | Pa Department Of Human Services | $6,354,000 | 22% |
| 2 | Illinois Department Of Healthcare & Family Services | $5,030,800 | 18% |
| 3 | Department Of Social Services Connecticut | $4,929,944 | 17% |
| 4 | Department Of Health Care Finance | $4,784,152 | 17% |
| 5 | North Carolina Department Of Health & Human Services | $4,729,520 | 17% |
| 6 | Health & Human Services, Rhode Island Executive Office Of | $1,419,924 | 5% |
| 7 | Mississippi Division Of Medicaid | $979,480 | 3% |
| 8 | Human Services Vermont Agency Of | $233,112 | 1% |
Federal obligations by fiscal year
| Fiscal year | Federal obligations |
|---|---|
| FY2026 | $15,060,729 |
| FY2025 | $13,400,203 |
| FY2011 | $680,000 |
Quick answers
What is Assistance Listing 93.885?
Assistance Listing 93.885 is Cell and Gene Therapy (CGT) Access Model, a federal grant program run by Centers for Medicare and Medicaid Services (Department of Health and Human Services).
What is the CFDA number for Cell and Gene Therapy (CGT) Access Model?
Its CFDA number is 93.885: Assistance Listing numbers were called CFDA numbers before 2018.
How much funding has Assistance Listing 93.885 awarded?
8 grant awards under 93.885 have obligated $28,460,932 in federal funds to 8 recipients.
Who receives the most funding from 93.885?
The recipients obligated the most under Cell and Gene Therapy (CGT) Access Model are Pa Department Of Human Services ($6,354,000), Illinois Department Of Healthcare & Family Services ($5,030,800) and Department Of Social Services Connecticut ($4,929,944).
How much did 93.885 obligate in fiscal year 2025?
Grants under 93.885 obligated $13,400,203 in federal funds in fiscal year 2025.
Are there open grant opportunities under 93.885?
No opportunity listed under 93.885 is open now. The latest, Cell and Gene Therapy (CGT) Access Model, was posted on June 12, 2024.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program